vs
Side-by-side financial comparison of Church & Dwight (CHD) and Charles River Laboratories (CRL). Click either name above to swap in a different company.
Church & Dwight is the larger business by last-quarter revenue ($1.5B vs $994.2M, roughly 1.5× Charles River Laboratories). Church & Dwight runs the higher net margin — 14.7% vs -27.8%, a 42.5% gap on every dollar of revenue. On growth, Church & Dwight posted the faster year-over-year revenue change (0.1% vs -0.8%). Over the past eight quarters, Charles River Laboratories's revenue compounded faster (-0.9% CAGR vs -1.4%).
Church & Dwight Co., Inc., is an American consumer goods company focusing on personal care, household products, and specialty products. The company was founded in 1847 and is headquartered in Ewing, New Jersey. It is the parent company of well-known brands such as Arm & Hammer, Trojan, OxiClean, and First Response. In 2022, Church & Dwight reported annual revenue of $5.4 billion. The company's products and services include a wide range of consumer goods, including laundry detergent, air fresh...
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
CHD vs CRL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $994.2M |
| Net Profit | $216.3M | $-276.6M |
| Gross Margin | 46.4% | — |
| Operating Margin | 19.8% | -28.5% |
| Net Margin | 14.7% | -27.8% |
| Revenue YoY | 0.1% | -0.8% |
| Net Profit YoY | -4.5% | -28.9% |
| EPS (diluted) | $0.91 | $-5.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.6B | $994.2M | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.5B | $984.2M | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.5B | $1.0B |
| Q1 26 | $216.3M | — | ||
| Q4 25 | $143.5M | $-276.6M | ||
| Q3 25 | $182.2M | $54.4M | ||
| Q2 25 | $191.0M | $52.3M | ||
| Q1 25 | $220.1M | $25.5M | ||
| Q4 24 | $189.2M | $-214.5M | ||
| Q3 24 | $-75.1M | $69.7M | ||
| Q2 24 | $243.5M | $94.1M |
| Q1 26 | 46.4% | — | ||
| Q4 25 | 45.8% | — | ||
| Q3 25 | 45.1% | — | ||
| Q2 25 | 43.0% | — | ||
| Q1 25 | 45.0% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 45.2% | 34.6% | ||
| Q2 24 | 47.1% | 34.5% |
| Q1 26 | 19.8% | — | ||
| Q4 25 | 16.2% | -28.5% | ||
| Q3 25 | 16.1% | 13.3% | ||
| Q2 25 | 17.4% | 9.7% | ||
| Q1 25 | 20.1% | 7.6% | ||
| Q4 24 | 16.2% | -16.7% | ||
| Q3 24 | -6.1% | 11.6% | ||
| Q2 24 | 22.3% | 14.8% |
| Q1 26 | 14.7% | — | ||
| Q4 25 | 8.7% | -27.8% | ||
| Q3 25 | 11.5% | 5.4% | ||
| Q2 25 | 12.7% | 5.1% | ||
| Q1 25 | 15.0% | 2.6% | ||
| Q4 24 | 12.0% | -21.4% | ||
| Q3 24 | -5.0% | 6.9% | ||
| Q2 24 | 16.1% | 9.2% |
| Q1 26 | $0.91 | — | ||
| Q4 25 | $0.60 | $-5.57 | ||
| Q3 25 | $0.75 | $1.10 | ||
| Q2 25 | $0.78 | $1.06 | ||
| Q1 25 | $0.89 | $0.50 | ||
| Q4 24 | $0.76 | $-4.17 | ||
| Q3 24 | $-0.31 | $1.33 | ||
| Q2 24 | $0.99 | $1.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $503.4M | $213.8M |
| Total DebtLower is stronger | $2.2B | $2.1B |
| Stockholders' EquityBook value | — | $3.2B |
| Total Assets | $9.0B | $7.1B |
| Debt / EquityLower = less leverage | — | 0.68× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $503.4M | — | ||
| Q4 25 | $409.0M | $213.8M | ||
| Q3 25 | $305.3M | $207.1M | ||
| Q2 25 | $923.2M | $182.8M | ||
| Q1 25 | $1.1B | $229.4M | ||
| Q4 24 | $964.1M | $194.6M | ||
| Q3 24 | $752.1M | $210.2M | ||
| Q2 24 | $491.7M | $179.2M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.1B | ||
| Q3 25 | $2.2B | $2.2B | ||
| Q2 25 | $2.2B | $2.3B | ||
| Q1 25 | $2.2B | $2.5B | ||
| Q4 24 | $2.2B | $2.2B | ||
| Q3 24 | $2.2B | $2.3B | ||
| Q2 24 | $2.2B | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | $4.0B | $3.2B | ||
| Q3 25 | $4.2B | $3.4B | ||
| Q2 25 | $4.4B | $3.4B | ||
| Q1 25 | $4.6B | $3.2B | ||
| Q4 24 | $4.4B | $3.5B | ||
| Q3 24 | $4.2B | $3.8B | ||
| Q2 24 | $4.3B | $3.7B |
| Q1 26 | $9.0B | — | ||
| Q4 25 | $8.9B | $7.1B | ||
| Q3 25 | $9.1B | $7.5B | ||
| Q2 25 | $8.8B | $7.6B | ||
| Q1 25 | $9.0B | $7.6B | ||
| Q4 24 | $8.9B | $7.5B | ||
| Q3 24 | $8.7B | $8.0B | ||
| Q2 24 | $8.8B | $7.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.55× | 0.68× | ||
| Q3 25 | 0.52× | 0.64× | ||
| Q2 25 | 0.50× | 0.70× | ||
| Q1 25 | 0.48× | 0.79× | ||
| Q4 24 | 0.51× | 0.65× | ||
| Q3 24 | 0.53× | 0.62× | ||
| Q2 24 | 0.51× | 0.65× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $147.5M |
| Free Cash FlowOCF − Capex | — | $58.6M |
| FCF MarginFCF / Revenue | — | 5.9% |
| Capex IntensityCapex / Revenue | — | 8.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $518.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $147.5M | ||
| Q3 25 | — | $213.8M | ||
| Q2 25 | — | $204.6M | ||
| Q1 25 | — | $171.7M | ||
| Q4 24 | $292.3M | $159.4M | ||
| Q3 24 | $364.0M | $251.8M | ||
| Q2 24 | $236.9M | $193.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $58.6M | ||
| Q3 25 | — | $178.2M | ||
| Q2 25 | — | $169.3M | ||
| Q1 25 | — | $112.4M | ||
| Q4 24 | $237.7M | $83.7M | ||
| Q3 24 | $315.4M | $213.1M | ||
| Q2 24 | $206.6M | $154.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | 15.0% | 8.4% | ||
| Q3 24 | 20.9% | 21.1% | ||
| Q2 24 | 13.7% | 15.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 8.9% | ||
| Q3 25 | 1.8% | 3.5% | ||
| Q2 25 | 1.5% | 3.4% | ||
| Q1 25 | 1.1% | 6.0% | ||
| Q4 24 | 3.5% | 7.5% | ||
| Q3 24 | 3.2% | 3.8% | ||
| Q2 24 | 2.0% | 3.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.93× | ||
| Q2 25 | — | 3.91× | ||
| Q1 25 | — | 6.74× | ||
| Q4 24 | 1.54× | — | ||
| Q3 24 | — | 3.61× | ||
| Q2 24 | 0.97× | 2.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHD
| Household Products | $641.6M | 44% |
| Personal Care Products | $476.1M | 32% |
| Consumer International | $273.9M | 19% |
| Specialty Products Division | $77.7M | 5% |
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
